Less than two years ago, Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company formed an alliance with the goal of bringing treatment to patients with diabetes. Now, the two companies are expected to present 30 diabetes related abstracts during the 72nd American Diabetes Association Scientific Sessions in Philadelphia from June 8-12.

The two companies will share data related to a wide variety of topics. One abstract will present information related to a novel basal insulin trial, and six abstracts will relate to empagliflozin. 

On June 6, Eli Lilly CEO John Lechleiter delivered the keynote address at the Financial Times U.S. Healthcare and Life Sciences Conference. He said that despite economic turmoil and political uncertainty regarding the direction of the U.S. healthcare system, innovation must continue in the pharmaceutical industry.

"Innovation requires long-term thinking, especially in an enterprise that typically requires more than a decade to bring a new medicine to patients," said Lechleiter. "We've stayed the course through challenging times in the past by following the science, and we need to maintain that same perspective today."